Skip to Content

'
Eric Jonasch, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1374
Houston, TX 77030
Phone: 713-792-2830

Education & Training

Degree-Granting Education

1988 McGill University, Montreal, Canada, BSc, Biochemistry

Board Certifications

11/2000 Medical Oncology American Board of Internal Medicine
2000 Oncology, Royal College of Physicians & Surgeons of Canada
2000 Medicine, Royal College of Physicians & Surgeons of Canada
11/1999 Hematology, American Board of Internal Medicine
8/1995 Internal Medicine, American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/2002-8/2009

Administrative Appointments/Responsibilities

Fellowship Program Director, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2008-present
Director, Von Hippel Lindau (VHL) Clinical Center, Houston, TX, 2003-present

Other Appointments/Responsibilities

Member, Graduate School of Biomedical Science, The University of Texas, Health Science Center, Houston, TX, 1/2004-present

Consultantships

Medical Advisory Board Member, Von Hippel Lindau (VHL) Family Alliance, Boston, MA, 2007-present
Member, Kidney Cancer Association Medical Advisory Board, Chicago, Illinois, 2004-present

Honors and Awards

2009 Young Texans Against Cancer Research Award
2008-present Renal Cell Carcinoma Translational Research, American University-Beirut
1997 Molecular Biology Research Seminar for Young Investigators, American Association for Cancer Research

Professional Memberships

American Association for Cancer Research (AACR)
Member, 1/1997-present
American Society of Clinical Oncology (ASCO)
Member, 7/2000-present
American Urological Association (AUA)
Member, Guideline Panel "Follow-Up of Observed and Definitively Treated Clinically Localized Renal Cell Cancer and Complex Renal Lesions", 5/2009-present
National Comprehensive Cancer Network (NCCN)
Member, Kidney & Testicular Cancers Panel, 3/2009-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Jonasch E, Corn P, Pagliaro L, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe R, Wright JJ, Tannir N. Upfront randomized phase II trial of sorafenib vs sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. In Press.
2. Daliani D, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ and Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456-60, Aug, 8/2009. e-Pub 3/2009. PMID: 19338544.
3. Montero A, Diaz-Montero C, Millikan R, Liu J, Do D-A, Hodges S, Jonasch E, McIntyre B, Hwu P, Tannir N. Cytokines and angiogenic factors in metastatic renal cell cancer: association of pretreatment serum levels with survivial. Ann Oncol, Jun 18, 6/2009. e-Pub 6/2009. PMID: 19541791.
4. Jonasch E, Wood CG, Matin S, Tu SM, Pagliaro LC, Aparicio AM, Tamboli P, Millikan RE, Wang X, Araujo J, Arap W, Tannir NM. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-4081, Sep 1, 6/2009. PMID: 19636008.
5. Zurita AJ, Jonasch E, Wu HK, Tran HT, Heymach JV. Circulating biomarkers for circular endothelial growth factors inhibitors in renal cell carcinoma. Cancer 115(S10), 05/15/2009. e-Pub 5/2009.
6. Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, Wood CG, Sandler CM. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics 29(3):741-54; discussion 755-7, May-Jun, 5/2009. PMID: 19448113.
7. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7(1):20-3, 1/2009. PMID: 19213663.
8. Kim J*, Jonasch E*, Alexander A, Short JD, Cai S, Wen S, Tsavachidou D, Tamboli P, Czerniak BA, Do KA, Wu KJ, Marlow LA, Wood CG, Copland JA, Walker CL. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 15(1):81-90, 1/2009. PMID: 19118035.
9. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. A randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 73(2):337-41, 2009. e-Pub 10/2008. PMID: 18950837.
10. Plimack ER, Tannir NM, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 115(9):1859-66, 2009. PMID: 19241453.
11. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3), Sep. e-Pub 7/2008. PMID: 18635226.
12. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180(1):94-8, Jul, 7/2008. e-Pub 5/2008. PMID: 18485389.
13. Rich TA, Jonasch E, Matin S, Waguespack SG, Gombos DS, Santarpia L, Stolle C, Jimenez C. A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma. Cancer Invest 26(6):642-6, Jul, 2008. PMID: 18584357.
14. Jonasch E, Tannir NM. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J 14(5):315-9. Review., Sep-Oct, 2008. PMID: 188.6336.
15. Margulis V, Wood CG, Jonasch E, Matin SF. Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep 10(3):253-8, May, 2008. PMID: 18765156.
16. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther 7(10), Oct 3. e-Pub 2008. PMID: 19018165.
17. Matin S, Ahrar K, Wood C, Daniels M, Jonasch E. Patterns of intervention for renal lesions in von Hippel-Lindau disease. BJU Int 102(8):940-45, Sep, 2008. e-Pub 2008. PMID: 18485044.
18. Jonasch E, Stadler WM, Bukowski RM, Hayes TG, Varadhachary A, Malik R, Figlin RA, Srinivas S. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer 113(1):72-7, Jul 1, 2008. PMID: 18484647.
19. Eisen T, Oudard S, Szczylik C, gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100(20), Oct 15. e-Pub 2008. PMCID: PMC2567417.
20. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98(8):1336-41, Apr 22, 2008. e-Pub 3/2008. PMID: 18362942.
21. Kassouf W, Sanchez-Ortiz R, Tamboli P,Jonasch E, Merchant MM, Spiess PE, Wood CG. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the MD Anderson Cancer Center Experience. Urology 69(5):835-838, 5/2007. PMID: 17482917.
22. Kassourf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol 178(5):1896-1900, Nov, 2007. e-Pub 9/2007. PMID: 17868729.
23. Kader AK, Tamboli P, Luongo T, Matin SF, Bell K, Jonasch E, Swanson DA, Wood CG. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol 177(3):855-60; discussion 860-1, Mar, 2007. PMID: 17296358.
24. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-36, 11/2003. PMID: 12881308.
25. Kim PN, Jonasch E, Mosterman BC, Mier JW, Janssen RA. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade. Cell Growth Differ 12(11):543-50, 11/2001. PMID: 11714635.
26. Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ, Mihm MA, Tanabe KK, Ott M, Haluska FG. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 89(2):356-62, 7/2000. PMID: 10918166.
27. Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J 6(3):139-45, 5/2000. PMID: 10882328.
28. Janssen RA, Veenstra KG, Jonasch P, Jonasch E, Mier JW. Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independent. J Biol Chem 273(48):32182-6, 11/1998. PMID: 9822696.

Invited Articles
1. Atkins M, George D, Jonasch, E. Immunotherapy of renal cell carcinoma. UptoDate, 2009.
2. Jonasch E. Current and emerging treatment options in advanced renal cell cancer. Adv Studies In Med 8(1):5-7, 2/2008.
3. Jonasch E. Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 7:73-8, 1/2007. PMID: 17187521.
4. Matin SF, Jonasch E. Targeting von Hippel-Lindau syndrome: the future is now. Future Oncol 2(3):321-3, 6/2006. PMID: 16787109.
5. Jonasch E. Melanoma: what the primary care physician needs to know. Primary Care Update for OB/GYNS 10(2):51-59, March-April, 2003.
6. Jonasch E. Melanoma vaccination: state-of-the-art and experimental approaches. Expert Rev Anticancer Ther 1:427-40, 10/2001. PMID: 12113109.
7. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6:34-55, 2001. PMID: 11161227.

Editorials
1. Jonasch E, Millikan R. Prognostic models: from the fates to the future. Cancer 115(10):2028-30, 2009. PMID: 19288573.

Abstracts
1. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with systemic therapy without cytoreductive nephrectomy. J Clin Oncol 27(15s) (#e16035), 5/2009.
2. Atkinson B, Hart J, Lin E, Tannir N, Jonasch E. Patients characteristics associated with dose-limiting sunitinib adverse events. J Clin Oncol 27(15s) (#e16110), 5/2009.
3. Johnson ED, Tannir NM, Olejeme KA, Logothetis CJ, Jonasch E. Survival benefit in bevacizumab based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol 27(15s) (#e16096), 5/2009.
4. Miller L, Lal LS, Tannir NM, DaCosta Byfield S, Atkinson B, Feng C, Lau JK, Yin L, Jonasch E. Treatment of poor-risk metastatic renal carcinoma patients with combination gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. J Clin Oncol 27(15s) (#e16112), 5/2009.
5. Matin SF, McCutcheon IE, Gombos DS, Waguespack SG, Wen S, Smith LA, Zhang Y, Davis DW, Fuller G, Jonasch E. Treatment of VHL patients with subitinib: Clinical observations and translational studies. J Clin Oncol 27(15s) (#e22047), 5/2009.
6. Heymach J, Jonasch E, Wang X, DU DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ. A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(15s) (#5114), 2009.
7. Jonasch E, Tsavachidou D, Wood CG, Matin SF, Corn PG, Tamboli P, Wang X, Tannir N. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(15s) (#5004), 2009.
8. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 26(15s) (#5093), 2008.
9. Dubauskas Z, Kunishige J, Prieto VG, Hwu P, Jonasch E, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib: a single institution experience. J Clin Oncol 26(15s) (#16101), 2008.
10. Plimack ER, Tannir NM, Bekele BN, Lin E, Jonasch E. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. Genitourinary Cancers Symposium 26(15s) (#5106), 2008.
11. Araujo JC, Jonasch E, Tannir N, Bekele BN, Lin E, Plimack ER. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. J Clin Oncol 26(15s) (#5106), 2008.
12. Jonasch E, Wood CG, Matin S, Tamboli P, Do K, Pagliaro LC, Aparicio AM, Araujo JC, Tannir NM. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma. J Clin Oncol 26(15s) (#5104), 2008.
13. Tsavachidou D, Tannir N, Thomas C, Mills G, Jonasch E. Reverse-phase protein array marker evaulation of protein expression patterns related to anti-angiogensis. J Clin Oncol 26(15s) (#16016), 2008.
14. Plimack E, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal carcinoma (ncc-RCC): a phase II study. J Clin Oncol 26(15s) (#5112), 2008.
15. Jonasch E, Corn P, Ash RG, Do K, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 25(18s) (#5104), 2007.
16. Tsavachidou D, Tannir NM, Wood CG, Corn P, Do K, Tamboli P, Smith LA, Matin S and Jonasch E. von Hippel-Lindau gene mutation status is associated with a dichotomous response in primary and metastatic tumors in patients receiving bevacizumab and erlotinib for metastatic renal cell carcinoma. J Clin Oncol 25(18s) (#15522), 2007.
17. Gao X, Reddy P, Dhanda K, Gondek K, Yeh YC, Stadler WM, Jonasch E. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. J Clin Oncol 24(18s) (#4604), 2006.
18. Jonasch E, Tsavachidou D, Wood C, Tamboli P, Tu S, Thomas C, Do KA, Matin S, Tannir NM. Presurgical treatment of metastatic renal cell carcinoma patients with bevacizumab and erlotinib: preliminary efficacy and biomarker data. European J of Can Suppl 4(12) (#80), 2006.
19. Srinivas S, Stadler WM, Bukowski R, Figlin R, Hayes T, Yankee EW,Jonasch E. Talactoferrin alfa may prolong progression-free survival in advanced renal cell carcinoma patients. J Clin Oncol 24(18s) (#4600), 2006.
20. Tannir NM, Jonasch E, McMicheal C, Wang X, Wooten L, Ng S. A phase II trial of gemcitabine plus capecitabine (GX) in patients with advanced renal cell cancer (mRCC) previously treated with immunotherapy. J Clin Oncol 23(16s) (#4598), 2005.
21. Jonasch E, Tu S-M, Tannir NM, Pagliaro LC, Mathew P, Siefker-Radtke A, Wen S, Wen S, General R,Lin S-H, Logothetis CJ. Bone-targeted therapy consisting of zoledronate, thalidomide, and gamma interferon in renal cell carcinoma; a phase II study. J Clin Oncol 23(16s) (#445s), 2005.
22. Jonasch E, Wen S, Thomas C, McDonnell T. Concordance between PTEN and p27 staining in primary and metastatic samples in a renal carcinoma tissue microarray. In: Proc Amer Assoc Cancer Res 46 (#3092), 2005.
23. Rodney AJ, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer with prior taxane exposure. J Clin Oncol 23(16s) (#4750), 2005.
24. Tannir NM, Wang X, Ng CS, Poulter VA, Mathew P, Siefker-Radtke AO, Jonasch E, Pagliaro LC, Cohen L, Millikan RE. A randomized phase III trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC). J Clin Oncol 23(14s) (#4607), 2004.
25. Haluska FG, Linette GP, Jonasch E, Hodi S, Longerich S, Yang S, Webb I, Stowell C, Kaplan J, Roberts B, Goldberg M. Immunologic gene therapy of melanoma: phase I study of therapy with autologous dendritic cells transduced with Rrcombinant adenoviruses encoding melanoma antigens. J Clin Oncol 19 (#1777), 2000.
26. Linette G, Jonasch E, Longerich S, Yang S, Webb I, Szczepiorkowski Z, Cheung A, Fee S, Haluska F. Phase I study of therapy with peptide-pulsed autologous dendritic cells for advanced melanoma. J Clin Oncol 19 (#1833), 2000.

Book Chapters
1. Jonasch E, Tannir NM. Targeted Therapy in Renal Cell Carcinoma. In: Targeted Therapy in Cancer. Humana Press: New Jersey, 305-16, 2007. PMID: 978-60327-423-4.
2. Jonasch E, Do KA, Logothetis C, McDonnell TJ. Issues and applications for tissue arrays in target and drug discovery. In: Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development. John Wiley and Sons, Inc., 73-90, 2004.
3. Jonasch E, Matin S, Wood CG, Pagliaro LC. Renal Cell Carcinoma. In: MD Anderson Manual of Clinical Oncology. McGraw-Hill, 757-84, 2000. PMID: 0-07-14199-1.
4. Jonasch E. Renal Neoplasia. In: Brenner and Rector’s The Kidney, 8th. Elsevier Science Publishers, 1342-67, 2000.

Grant & Contract Support

Title: Determinants of Response and Resistance to Targeted Therapy in Renal Cell Carcinoma
Funding Source: UT MDACC
Role: Principal Investigator
Duration: 10/2008 - 10/2009
 
Title: High Throughput Screen for TRiC Deficient VHL Mutations
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/30/2007 - 9/30/2010
 
Title: Evaluation of FGF Receptor Activation State in Renal Cell Carcinoma.
Funding Source: Bristol Myers Squibb
Role: Principal Investigator
 
Title: Retrospective genetic and immunohistochemical analysis on primary and matched metastatic renal cell carcinoma specimens
Funding Source: University of Texas M.D. Anderson Cancer Center Institutional Research Grant
Role: Principal Investigator

Last updated: 9/25/2009